VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ — Zero Candida (the “Company” or “ZC”) (TSXV: ZCT), an Israeli FemTech medical device start-up, is pleased to announce the Company has received a final patent from South Africa PCT patent PCT-IL 2023050243 in South Africa. In addition, the company is actively pursuing a global patent portfolio with applications filed worldwide including in the United States, Brazil, and Europe.
Public Announcements
- Zero Candida
Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device
Zero Candida Technologies, Inc. (TSXV: ZCT)(OTCQB: ZCTFF)(FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device company focused on revolutionizing women’s health, is pleased to…
- Zero Candida
Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update
Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a Femtech company developing a SMART, AI-driven medical device to…
- Zero Candida
Zero Candida Technologies Announces DTC Eligibility and to Present at OTCQB Venture Virtual Investor Conference on August 7th
VANCOUVER, BC, Aug. 5, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…
- Zero Candida
Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device
Zero Candida Technologies, Inc. (TSXV: ZCT)(OTCQB: ZCTFF)(FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device company focused on revolutionizing women’s health, is pleased to…
- Zero Candida
Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update
Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a Femtech company developing a SMART, AI-driven medical device to…
- Zero Candida
Zero Candida Technologies Announces DTC Eligibility and to Present at OTCQB Venture Virtual Investor Conference on August 7th
VANCOUVER, BC, Aug. 5, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…
- Zero Candida
Zero Candida Technologies Reports Full Year 2024 Financial Results and Business Highlights
VANCOUVER, BC, April 2, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…
- Zero Candida
Zero Candida Commences Trading on OTCQB Market
VANCOUVER, BC, March 12, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…
- Zero Candida
Moore Market analysis: Zero Candida potential market will reach over $2 Billion by 2030
VANCOUVER, BC, Feb. 3, 2025 /PRNewswire/ — A market analysis made by Moore Financial Consulting published today estimate the global market for Zero Candida Technologies,…
- Zero Candida
Zero Candida Announces Successful Listing on Frankfurt Stock Exchange and Details of Investor Webinar
VANCOUVER, BC, Jan. 16, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company…
- Zero Candida
Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025
VANCOUVER, BC, January 06, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company…
- Zero Candida
Zero Candida Announces Full Transaction and Being Trading November 25th on the TSX Venture Exchange (Canada)
VANCOUVER, BC, Nov. 25, 2024 /PRNewswire/ — Zero Candida (the “Company” or “ZCT”), (TSXV: ZCT) an Israeli FemTech medical device start-up, is pleased to announce…
- Zero Candida
Zero Candida Announces TSX Venture Exchange Listing Date
Zero Candida (formerly 1319743 B.C. Ltd.), has recently completed its business acquisition of Zero Candida Ltd., an Israeli private company (“ZC” and “Acquisition” respectively). In…
